American Society of Hirudotherapy

Cadmium selenide quantum dot-zinc oxide composite: Synthesis, characterization, dye removal ability with UV irradiation, and antibacterial activity as a safe and high-performance photocatalyst

Research article published in Journal of photochemistry and photobiology. B, Biology (2018)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportDrug DevelopmentMahmoodi NM et al. · Journal of photochemistry and photobiology. B, Biology, 2018

Abstract

In this paper, cadmium selenide quantum dot (CdSe QD)-zinc oxide (ZnO) nanocomposite (CdSe QD-ZnO) was synthesized and characterized and its photocatalytic dye degradation ability was investigated. The XRD, FTIR, UV-Vis, AFM and SEM were used to characterize the synthesized nanomaterials. The correlation coefficient of pseudo-first-order kinetic reaction is 0.98. The rate constants from 20 to 30 mg/L of pollutant concentrations was reduced by the order of 0.9. The temporal change in dye concentration reduces as the photocatalyst dosage increase up to optimum value of 0.04 g/L, then beyond that value the increase in the dosage becomes detrimental. Antibacterial activity of the synthesized nanocomposite as a safe photocatalyst was studied in details. Antibacterial activity of as prepared samples was also examined against Escherichia coli (E. coli). For in vitro study, Human umbilical vein endothelial cells (HUVEC) was utilized for the modeling of toxicity of each as prepared samples as representative of human normal cell line. In vivo study was conducted using leeches (Hirudo orientalis). In the presence of ethanol as hydroxyl radical (OH) scavenger, the removal efficiency significantly depresses compared to the di methyl sulfoxide as electron scavengers suggesting OH possesses a major role in photocatalytic dye (Basic Red 18: BR18) decolorization. By coupling with CdSe QD, the zone of inhibition was greatly increased suggesting the size dependent inactivation of E. coli. The results presented that the composite had no significant effect on the proliferation of HUVEC normal cells. In addition, the treatment of cells with ZnO and the composite does not impact on the cell morphology.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsAnimalsAnti-Bacterial AgentsCadmium CompoundsCatalysisCell ProliferationColoring AgentsEscherichia coliHuman Umbilical Vein Endothelial CellsHumansHydroxyl RadicalLeechesMicroscopy, Atomic Force

Summary

In this paper, cadmium selenide quantum dot (CdSe QD)-zinc oxide (ZnO) nanocomposite (CdSe QD-ZnO) was synthesized and characterized and its photocatalytic dye degradation ability was investigated.

Why This Matters for Hirudotherapy

This materials science study synthesized a cadmium selenide quantum dot-zinc oxide nanocomposite, evaluating its photocatalytic dye degradation and antibacterial activity against E. coli, with in vivo toxicity testing conducted using Hirudo orientalis leeches as a model organism alongside HUVEC cell-line studies. For ASH's domain, leeches appear here solely as a biological toxicity model—not as a therapeutic agent, a source of bioactive compounds, or in any hirudotherapy context. The study is entirely unrelated to the leech secretome, anticoagulation, or any therapeutic application of leeches. There is no defensible relevance to ASH's research library.

Citation

Cadmium selenide quantum dot-zinc oxide composite: Synthesis, characterization, dye removal ability with UV irradiation, and antibacterial activity as a safe and high-performance photocatalyst

Mahmoodi NM et al. · Journal of photochemistry and photobiology. B, Biology, 2018

Added to ASH library: May 27, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.